A recent study published in Epilepsia showed that the selective serotonin receptor agonist bexicaserin was well tolerated and effective at reducing motor seizure frequency across a variety of DEE types. While seizure endpoints may be only one of the priorities for the KCNQ2 community, this study’s successful use of a broad category (“DEE Other”) alongside Dravet and Lennox-Gastaut syndromes opens the door for future researchers to use this designation. By showing significant clinical improvement in a diverse pool of people, they provide evidence that aggregating multiple DEEs is a viable approach. Findings like these could lead to increased inclusion of multiple DEEs in future clinical trials.

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.18689